News | June 15, 2024
Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Subscribe To Our Newsletter & Stay Updated
